Chase Kempinski | Chief Executive Officer, Co-Founder
Evax Inc.

Chase Kempinski, PhD, is a synthetic biologist and biotech entrepreneur focused on enabling scalable, next-generation vaccine adjuvants. He is the Co-Founder and CEO of Enepret, Inc., and EVAX, Inc., where he leads the development and manufacturing of renewable, yeast-derived triterpene oils for pharmaceutical excipients and emulsion-based vaccine adjuvants. His work integrates metabolic engineering, process development, and translational immunology to address supply and formulation constraints in modern adjuvant systems. Dr. Kempinski serves as the principal investigator on multiple NIH-funded programs supporting synthetic biology–enabled adjuvant manufacturing and combination adjuvant strategies for vaccines and has authored numerous peer-reviewed publications on terpene metabolism and metabolic engineering. His current focus is on commercializing empowering technologies and engaging with collaborators and industry partners.